Drugs / TAK-901
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00935844 | Oct 2009 → Aug 2011 | cancer, lymphoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00807677 | Mar 2009 → Sep 2012 | Waldenstrom macroglobulinemia, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +5 | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00935844 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL3544932 ↗ |
| Modality | Small molecule | — CHEMBL3544932 ↗ |
| Route | Intravenous | “via IV infusion” NCT00807677 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL3544932 ↗ |